ISSUES OF CONVENTIONAL META-ANALYSIS FOR TIME-TO-EVENT OUTCOMES: REANALYSIS RESULTS OF THE EFFICACY AND SAFETY OF NOVEL ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION USING RECONSTRUCTED INDIVIDUAL-LEVEL DATA

@inproceedings{Kaneko2016ISSUESOC,
  title={ISSUES OF CONVENTIONAL META-ANALYSIS FOR TIME-TO-EVENT OUTCOMES: REANALYSIS RESULTS OF THE EFFICACY AND SAFETY OF NOVEL ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION USING RECONSTRUCTED INDIVIDUAL-LEVEL DATA},
  author={Masayuki Kaneko and Hajime Uno},
  year={2016}
}
Previous meta-analysis has reported that novel oral anticoagulants (NOAC), dabigatran, rivaroxaban, apixaban, and edoxaban, significantly decreased stroke or systemic embolic events (SEE) by 19% compared to warfarin, and the reduction in major bleeding (MB) was not significant using Relative Risk ( 

Topics from this paper.

Similar Papers